BioAge Labs Inc. (NASDAQ: BIOA) is a Healthcare company (Biotechnology) with a market capitalization of $192M. The Maz Rating grades it against the other companies in its sector.
BioAge Labs Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $5.10, BioAge Labs Inc. trades at 22.3x sales and 0.7x book value. Over the last twelve months it generated about $9M of revenue and a net loss of $96M. It runs a gross margin of 99.3%, an operating margin of -1401.8% and a net margin of -1253.6%. It shows return on equity of -31.4%, return on invested capital of -34.5% and a free cash flow yield of -53.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 15.51. Over the past 52 weeks the share price ranged from $4.81 to $25.96, with a beta of 0.94.
BioAge Labs Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 6 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.